Responses to CAR T-cell therapy deepen over time for lymphoma – Healio
|
Responses to CAR T-cell therapy deepen over time for lymphoma
Healio Earlier results from ZUMA-1 showed axicabtagene ciloleucel (Yescarta; Kite Pharma, Gilead) — an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy — induced significant clinical benefit with a manageable safety profile for patients with … |
